EyePoint announces $175 million stock offering following record surge in share price
EyePoint Pharmaceuticals Inc. (EYPT) announced Monday afternoon that it has begun an underwritten public offering of $175 million in common stock. The company will also give underwriters the chance to purchase up to an additional $26.25 million of stock at the offering price, for 30 days, less an underwriting discount. The offering comes after EyePoint shares surged 177% in Monday's regular session following its announcement of upbeat data for its macular degeneration treatment EYP-1901. That was the stock's largest one-day percentage gain on record. EyePoint shares are up a further 6% in after-hours trading. The company said in a release that it would use the net proceeds from the stock offering to advance EYP-1901's clinical development "through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials." EyePoint will also use proceeds to support earlier-stage pipeline-development efforts.
-Emily Bary
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-04-23 1706ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track